Business
Notice of Results
Notice of Results.
About this update from Immupharma Plc
[{"type":"text","content":"\n \nRNS Number : 2726W Immupharma PLC 26 April 2016 \n\n\n\n\n\nRNS : FOR IMMEDIATE RELEASE\n\n\n26 APRIL 2016\n \n\n\n\n\n \n \nNOTIFICATION OF PRELIMINARY RESULTS\nDate: 4 May 2016\n \n \nImmuPharma PLC (LSE:IMM), (\"ImmuPharma\" or the \"Company\"), the specialist drug discovery and development company confirms that it will announce its Preliminary results for the year ended 31 December 2015 on Wednesday 4 May 2016.\n \n \nFor further information on meetings scheduled around the Preliminary results roadshow or media enquiries, please contact Lisa Baderoon on [email protected].\n \n \n \n-Ends-\n \n\n\n\n\nFor further information please contact:\n \n\n\n\n\nImmuPharma plc (www.immupharma.org)\n\n\n+ 44 (0) 20 7152 4080\n\n\n\n\nTim McCarthy, Chairman\n\n\n\n\n\n\n\nLisa Baderoon, Head of Investor Relations\nTwitter: @immupharma\n \n\n\n + 44 (0) 7721 413496\n \n \n\n\n\n\n \nPanmure, Gordon & Co., NOMAD & Broker\n\n\n \n+44 (0) 20 7886 2500\n\n\n\n\nFred Walsh, Duncan Monteith, Corporate Finance\nCharles Leigh-Pemberton, Corporate Broking\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nNotes to Editors\n \nImmuPharma PLC \n \nImmuPharma is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange (LSE:IMM), focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma is led by a commercially focused Board and management team with extensive experience. \n \nImmuPharma announced on 1 March 2016 the successful completion of a £8.4 million fund raise, comprising a Placing and Subscription together with confirmation of EIS and VCT qualifying status. Monies raised will principally be used to complete the pivotal Phase III trial of Lupuzor™. Following the issue of the New Ordinary Shares referred to above, ImmuPharma will have 121,781,219 ordinary shares of 10 pence each (the \"Ordinary Shares\") in issue.\n \nLupuzorTM \n \nLupuzorTM (also referred to as forigerimod, rigerimod, IPP-201101 or P140 is ImmuPharma's lead compound and a potential treatment for lupus (or Systemic Lupus Erythematosus), a chronic, potentially life-threatening auto-immune diseas...